about
Antidepressants for smoking cessationPharmacological interventions for smoking cessation: an overview and network meta-analysisAntidepressants for smoking cessationInsights into CYP2B6-mediated drug-drug interactionsAn S-warfarin and AZD1981 interaction: in vitro and clinical pilot data suggest the N-deacetylated amino acid metabolite as the primary perpetrator.Coprescription of tamoxifen and medications that inhibit CYP2D6.Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots.Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patientsBupropion: pharmacology and therapeutic applications.Sucralose, a synthetic organochlorine sweetener: overview of biological issuesThe use of bupropion SR in cigarette smoking cessationAddressing phenoconversion: the Achilles' heel of personalized medicine.Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatmentImpact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans.Effect of bupropion on sexual dysfunction.Antidepressant-drug interactions are potentially but rarely clinically significant.Bupropion for weight reduction.A preliminary study of sustained-release bupropion for smoking cessation in bipolar disorder.Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion.Antidepressants, metoprolol and the risk of bradycardiaBupropion extended-release for depressive disorders.Treatment of comorbid tobacco use in people with serious mental illness.A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophreniaClinically significant drug interactions with newer antidepressants.Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products.In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation.Bupropion-warfarin combination: a serious complication.Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers.How frequently are contraindicated or warned against combinations of drugs prescribed to patients receiving long-term opioid therapy for chronic pain?Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model.Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.Pharmacokinetics, Safety, and Tolerability of Vortioxetine Following Single- and Multiple-Dose Administration in Healthy Japanese Adults.Chirality and neuropsychiatric drugs: an update on stereoselective disposition and clinical pharmacokinetics of bupropion.Delirium associated with concomitant use of duloxetine and bupropion in an elderly patient.VX-509 (Decernotinib)-Mediated CYP3A Time-Dependent Inhibition: An Aldehyde Oxidase Metabolite as a Perpetrator of Drug-Drug Interactions.Use of Human Plasma Samples to Identify Circulating Drug Metabolites that Inhibit Cytochrome P450 Enzymes.CYP450 genotype and pharmacogenetic association studies: a critical appraisal
P2860
Q24201167-DB067F26-85DE-4746-9664-88ED28C2DB2DQ24202961-DF3D0399-A6E6-4421-913A-0ABBC82FA823Q24246426-91370D97-21EA-4A41-A79C-CCC31674EC04Q28078857-64B9CA70-5E62-44CE-83DE-A4E170A6431CQ31123470-D7FFEDCF-14B5-430B-86E8-D5D3ED71110EQ33898184-9D933D23-9736-452D-9319-F44A32302D90Q34116690-C8E289D1-9CD2-4BD0-9F47-7069A97612D4Q34346501-A3DD225F-CBB2-4B8F-862F-34FFADFCFC31Q34569990-1DCDD935-BD0D-4AA0-BF5C-5B42A60D56FAQ34657381-B6AFDCA2-F56B-438D-B700-C9DDCEA5E78AQ34779470-4FEFAD6D-3226-480E-AF4A-4A3A39104FB3Q35023701-E6434207-B438-4C18-8ED5-E1FA289AB39CQ35097430-0BD70BA5-42A8-4031-8436-1302EEB755BCQ35617340-04ED7363-EBCF-4A7F-91CF-6EA41859B8EEQ35953819-7347EDE1-E459-41DA-9D30-F4DC6A36C5A5Q36313107-1796A372-CE9A-4F30-B05E-A1AC706ABDF1Q36538987-F5D40A14-1B60-495E-9256-C1A7FFD78793Q36691753-538DD202-A00B-4C6D-85C0-E6DDBF90BA5DQ36934843-15D45D14-140C-426B-82C7-64AFF4698D1BQ36972675-A1F77DD3-4CA5-4FA1-91EE-F14FE99B0288Q37079028-369A2C43-5C30-49B0-B0CB-94C4A101D887Q37154793-B3C6720C-1C05-4516-B444-D18BBECD76E6Q37173735-DAE9F7D4-540D-48FD-9A79-4E9F9AABFCC6Q37218646-3919ACDF-FE91-45B7-BF52-248590F12AB2Q37968621-3BB10E25-D09C-4E4D-AFDB-7434775E5467Q38815352-3B46DD43-BDDA-4367-8B99-80C62B39A97DQ39194285-73FDEE31-DB35-412B-8217-94AE1134B6E0Q41850693-0A46867A-C451-40F8-B5A3-646CE6EFFDFCQ42407006-607CF94C-BDAA-40D7-A7DA-001A02410032Q44284711-2EDB7753-E1D1-41AE-AA97-612FAA2C152CQ47267937-681D7657-AE8A-4A44-A99F-F7B17737BE22Q47449167-CA131AB3-37DD-4BC6-A628-AA26CDC9069FQ47760557-650CBD86-95F6-44AC-8485-03F0B5F513DFQ48027985-02A40A3D-41AE-47AD-AF4F-F284D233BA1AQ48059118-EE0D1B9E-D9BC-4F3D-BF82-D3E60AD3A2C7Q53081552-34FCCE89-6209-4159-AC1C-C74E0DC4BF2AQ53085269-E2D559F5-41C0-4E84-BB0A-8F20A89F53CBQ57585515-60F63750-AF5D-4DC5-9801-ADF3494F4F58
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Inhibition of CYP2D6 activity by bupropion.
@ast
Inhibition of CYP2D6 activity by bupropion.
@en
type
label
Inhibition of CYP2D6 activity by bupropion.
@ast
Inhibition of CYP2D6 activity by bupropion.
@en
prefLabel
Inhibition of CYP2D6 activity by bupropion.
@ast
Inhibition of CYP2D6 activity by bupropion.
@en
P2093
P1476
Inhibition of CYP2D6 activity by bupropion.
@en
P2093
Carrie A Bronars
David E Adson
Dorothy K Hatsukami
Jennifer Harris
Lisa H Brauer
Michael Kotlyar
Timothy S Tracy
P304
P356
10.1097/01.JCP.0000162805.46453.E3
P407
P577
2005-06-01T00:00:00Z